STOCK TITAN

[Form 4] MARIMED INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jon R. Levine, who is listed as President and CEO, Director, and a 10% owner of Marimed Inc. (MRMD), reported transactions on 10/02/2025. 11,517 restricted stock units (RSUs) vested and were converted one-for-one into common shares; the filing shows an acquisition of 11,517 shares at a $0 price component and a separate disposition of 3,381 shares withheld by the issuer to satisfy tax-withholding obligations at a price of $0.161 per share. After these reported transactions, the filing lists 20,855,370 shares beneficially owned directly and 6,684,640 shares held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children (the reporting person disclaims beneficial ownership of the trust shares). The RSU grant referenced was originally awarded on April 2, 2024 and remaining installments vest in three equal parts on April 2, 2026, October 2, 2026, and April 2, 2027.

Jon R. Levine, che è elencato come Presidente e CEO, Direttore e proprietario del 10% di Marimed Inc. (MRMD), ha riportato operazioni il 10/02/2025. 11.517 unità di azioni soggette a restrizioni (RSU) si sono maturate e sono state convertite una a una in azioni ordinarie; la dichiarazione mostra un’acquisizione di 11.517 azioni con componente prezzo pari a $0 e una separata disposizione di 3.381 azioni trattenute dall’emittente per soddisfare obblighi di ritenuta fiscale al prezzo di $0,161 per azione. Dopo queste operazioni riportate, la dichiarazione indica 20.855.370 azioni detenute direttamente e 6.684.640 azioni detenute indirettamente dal Jon Levine Family Trust a beneficio della sua coniuge e dei figli (la persona che segnala si dissocia dalla proprietà vantaggiosa delle azioni del trust). Il grant RSU di cui si fa riferimento era originariamente assegnato il 2 aprile 2024 e i restanti ratei matureranno in tre parti uguali il 2 aprile 2026, il 2 ottobre 2026 e il 2 aprile 2027.

Jon R. Levine, quien figura como Presidente y CEO, Director y propietario del 10% de Marimed Inc. (MRMD), reportó transacciones el 10/02/2025. 11,517 unidades de acciones restringidas (RSUs) vestidas y convertidas una por una en acciones comunes; la declaración muestra una adquisición de 11,517 acciones con un componente de precio de $0 y una disposición separada de 3,381 acciones retenidas por el emisor para satisfacer obligaciones de retención fiscal a un precio de $0,161 por acción. Después de estas transacciones reportadas, la declaración lista 20,855,370 acciones titularidad directa y 6,684,640 acciones mantenidas indirectamente por el Jon Levine Family Trust para el beneficio de su cónyuge e hijos (la persona que reporta renuncia a la propiedad beneficiosa de las acciones del trust). El otorgamiento de RSU mencionado fue originalmente otorgado el 2 de abril de 2024 y los acuerdos restantes vencen en tres partes iguales el 2 de abril de 2026, el 2 de octubre de 2026 y el 2 de abril de 2027.

Jon R. Levine은 Marimed Inc. (MRMD)의 사장 겸 CEO, 이사, 및 10% 소유주로 기재되었으며, 2025-10-02에 거래를 보고했습니다. 11,517주의 제한 주식단위(RSUs)가 확정되어 일반 주식으로 1대1로 전환되었습니다; 공시에는 11,517주를 매입한 것으로 기재되고 가격 구성 요소가 $0인 반면, 3,381주는 발행자가 세금 원천징수를 충당하기 위해 보류하였고 주당 가격은 $0.161입니다. 이 보고된 거래 이후, 공시에는 Jon Levine 가족 신탁이 배우자와 자녀를 위해 직접 보유한 20,855,370주와 간접 보유한 6,684,640주가 기재되며(공시는 신탁 주식에 대한 유익한 소유를 부인합니다). 언급된 RSU 부여는 원래 2024-04-02에 수여되었고 남은 분할은 2026-04-02, 2026-10-02, 2027-04-02에 각각 3분의 1로 베스팅됩니다.

Jon R. Levine, qui est inscrit en tant que Président et CEO, Directeur et propriétaire à 10% de Marimed Inc. (MRMD), a déclaré des transactions le 02/10/2025. 11 517 unités d’actions restreintes (RSU) se sont acquises et ont été converties une pour une en actions ordinaires; le dossier montre une acquisition de 11 517 actions à un composant de prix de $0 et une cession distincte de 3 381 actions retenues par l’émetteur pour satisfaire les obligations de retenue d’impôt à un prix de $0,161 par action. Après ces transactions déclarées, le dossier indique 20 855 370 actions détenues directement et 6 684 640 actions détenues indirectement par le Jon Levine Family Trust au profit de son épouse et de ses enfants (la personne qui déclare se déclare ne pas avoir l’usufruit des actions du trust). La bourse RSU mentionnée avait été initialement accordée le 2 avril 2024 et les versements restants vestent en trois parties égales le 2 avril 2026, le 2 octobre 2026, et le 2 avril 2027.

Jon R. Levine, der als Präsident und CEO, Direktor und 10% Eigentümer von Marimed Inc. (MRMD) aufgeführt wird, meldete Transaktionen am 02.10.2025. 11.517 eingeschränkte Aktien (RSUs) vesteten und wurden eins-zu-eins in Stammaktien umgewandelt; die Meldung zeigt den Erwerb von 11.517 Aktien zu einer Preis-Komponente von $0 und eine getrennte Veräußerung von 3.381 Aktien, die vom Emittenten einbehalten wurden, um Steuerrückstellungen zu erfüllen, zu einem Preis von $0,161 pro Aktie. Nach diesen gemeldeten Transaktionen listet die Meldung direkt gehaltene 20.855.370 Aktien und indirekt gehaltene 6.684.640 Aktien durch den Jon Levine Family Trust zugunsten seines Ehepartners und seiner Kinder (die meldende Person bestreitet die wirtschaftliche Beneficial Ownership der Trust-Aktien). Der erwähnte RSU-Beschluss wurde ursprünglich am 2. April 2024 gewährt und verbleibende Raten vesten in drei gleichen Teilen am 2. April 2026, am 2. Oktober 2026 und am 2. April 2027.

جون R. ليفين، الذي يُذكر كـ رئيس تنفيذي ورئيس مجلس الإدارة، ومدير، ومالك بنسبة 10% من شركة Marimed Inc. (MRMD)، أبلغ عن صفقات في 02/10/2025. تم تحסטير 11,517 وحدة أسهم مقيدة (RSUs) وتحويلها واحد مقابل واحد إلى أسهم عادية؛ يظهر الإبلاغ امتلاك 11,517 سهماً بعنصر سعر يساوي $0، وبيع منفصل لـ3,381 سهماً تم احتجازها من قبل المصدر للوفاء بالتزامات الخصم الضريبي بسعر $0.161 للسهم. بعد هذه الصفقات المبلغ عنها، يسرد الإبلاغ 20,855,370 سهماً مملوكة بشكل مباشر و6,684,640 سهماً مملوكة بشكل غير مباشر بواسطة Jon Levine Family Trust لصالح زوجته وأطفاله (المبلغ عنه ينفي الملكية المفيدة لأسهم الثقة). المنحة RSU المذكورة كانت منحت أصلاً في 2 أبريل 2024 وتُستكمل الأقساط المتبقية بانتظام ثلاثاً في 2 أبريل 2026، 2 أكتوبر 2026، و2 أبريل 2027.

Jon R. Levine,被列为 总裁兼首席执行官董事,以及 Marimed Inc. (MRMD) 的 10% 所有者,在 2025/10/02 报告交易。11,517份受限股票单位(RSU)已归属并按一对一转换为普通股;申报显示以 $0 的价格组成获得了 11,517 股,并有一笔单独处置的 3,381 股由发行人扣留以满足税收预扣义务,价格为每股 $0.161。在这些交易之后,申报列出直接持有的 20,855,370 股,以及 Jon Levine Family Trust 间接持有的 6,684,640 股,以其配偶及子女受益(报告人对信托股票的受益所有权予以否认)。所提及的 RSU 授予最初于 2024年4月2日 授予,剩余分期将在 2026年4月2日2026年10月2日2027年4月2日 分三等份归属。

Positive
  • 11,517 RSUs vested and converted to common shares, increasing the reporting person's direct holdings
  • Direct beneficial ownership after transactions remains substantial at 20,855,370 shares
Negative
  • 3,381 shares were withheld by the issuer to satisfy tax-withholding obligations
  • A large block of 6,684,640 shares is held indirectly in a family trust (reporting person disclaims beneficial ownership)

Insights

TL;DR: CEO Jon R. Levine had 11,517 RSUs vest and increased reported direct holdings to 20,855,370 shares after tax withholding of 3,381 shares.

The filing documents the vesting conversion of 11,517 RSUs into common stock on 10/02/2025, with the issuer withholding 3,381 shares to satisfy taxes at a price shown as $0.161 per share.

The report also discloses 6,684,640 shares held indirectly in the Jon Levine Family Trust, which the reporting person disclaims beneficial ownership of; the filing therefore separates direct and indirect positions explicitly.

Jon R. Levine, che è elencato come Presidente e CEO, Direttore e proprietario del 10% di Marimed Inc. (MRMD), ha riportato operazioni il 10/02/2025. 11.517 unità di azioni soggette a restrizioni (RSU) si sono maturate e sono state convertite una a una in azioni ordinarie; la dichiarazione mostra un’acquisizione di 11.517 azioni con componente prezzo pari a $0 e una separata disposizione di 3.381 azioni trattenute dall’emittente per soddisfare obblighi di ritenuta fiscale al prezzo di $0,161 per azione. Dopo queste operazioni riportate, la dichiarazione indica 20.855.370 azioni detenute direttamente e 6.684.640 azioni detenute indirettamente dal Jon Levine Family Trust a beneficio della sua coniuge e dei figli (la persona che segnala si dissocia dalla proprietà vantaggiosa delle azioni del trust). Il grant RSU di cui si fa riferimento era originariamente assegnato il 2 aprile 2024 e i restanti ratei matureranno in tre parti uguali il 2 aprile 2026, il 2 ottobre 2026 e il 2 aprile 2027.

Jon R. Levine, quien figura como Presidente y CEO, Director y propietario del 10% de Marimed Inc. (MRMD), reportó transacciones el 10/02/2025. 11,517 unidades de acciones restringidas (RSUs) vestidas y convertidas una por una en acciones comunes; la declaración muestra una adquisición de 11,517 acciones con un componente de precio de $0 y una disposición separada de 3,381 acciones retenidas por el emisor para satisfacer obligaciones de retención fiscal a un precio de $0,161 por acción. Después de estas transacciones reportadas, la declaración lista 20,855,370 acciones titularidad directa y 6,684,640 acciones mantenidas indirectamente por el Jon Levine Family Trust para el beneficio de su cónyuge e hijos (la persona que reporta renuncia a la propiedad beneficiosa de las acciones del trust). El otorgamiento de RSU mencionado fue originalmente otorgado el 2 de abril de 2024 y los acuerdos restantes vencen en tres partes iguales el 2 de abril de 2026, el 2 de octubre de 2026 y el 2 de abril de 2027.

Jon R. Levine은 Marimed Inc. (MRMD)의 사장 겸 CEO, 이사, 및 10% 소유주로 기재되었으며, 2025-10-02에 거래를 보고했습니다. 11,517주의 제한 주식단위(RSUs)가 확정되어 일반 주식으로 1대1로 전환되었습니다; 공시에는 11,517주를 매입한 것으로 기재되고 가격 구성 요소가 $0인 반면, 3,381주는 발행자가 세금 원천징수를 충당하기 위해 보류하였고 주당 가격은 $0.161입니다. 이 보고된 거래 이후, 공시에는 Jon Levine 가족 신탁이 배우자와 자녀를 위해 직접 보유한 20,855,370주와 간접 보유한 6,684,640주가 기재되며(공시는 신탁 주식에 대한 유익한 소유를 부인합니다). 언급된 RSU 부여는 원래 2024-04-02에 수여되었고 남은 분할은 2026-04-02, 2026-10-02, 2027-04-02에 각각 3분의 1로 베스팅됩니다.

Jon R. Levine, qui est inscrit en tant que Président et CEO, Directeur et propriétaire à 10% de Marimed Inc. (MRMD), a déclaré des transactions le 02/10/2025. 11 517 unités d’actions restreintes (RSU) se sont acquises et ont été converties une pour une en actions ordinaires; le dossier montre une acquisition de 11 517 actions à un composant de prix de $0 et une cession distincte de 3 381 actions retenues par l’émetteur pour satisfaire les obligations de retenue d’impôt à un prix de $0,161 par action. Après ces transactions déclarées, le dossier indique 20 855 370 actions détenues directement et 6 684 640 actions détenues indirectement par le Jon Levine Family Trust au profit de son épouse et de ses enfants (la personne qui déclare se déclare ne pas avoir l’usufruit des actions du trust). La bourse RSU mentionnée avait été initialement accordée le 2 avril 2024 et les versements restants vestent en trois parties égales le 2 avril 2026, le 2 octobre 2026, et le 2 avril 2027.

Jon R. Levine, der als Präsident und CEO, Direktor und 10% Eigentümer von Marimed Inc. (MRMD) aufgeführt wird, meldete Transaktionen am 02.10.2025. 11.517 eingeschränkte Aktien (RSUs) vesteten und wurden eins-zu-eins in Stammaktien umgewandelt; die Meldung zeigt den Erwerb von 11.517 Aktien zu einer Preis-Komponente von $0 und eine getrennte Veräußerung von 3.381 Aktien, die vom Emittenten einbehalten wurden, um Steuerrückstellungen zu erfüllen, zu einem Preis von $0,161 pro Aktie. Nach diesen gemeldeten Transaktionen listet die Meldung direkt gehaltene 20.855.370 Aktien und indirekt gehaltene 6.684.640 Aktien durch den Jon Levine Family Trust zugunsten seines Ehepartners und seiner Kinder (die meldende Person bestreitet die wirtschaftliche Beneficial Ownership der Trust-Aktien). Der erwähnte RSU-Beschluss wurde ursprünglich am 2. April 2024 gewährt und verbleibende Raten vesten in drei gleichen Teilen am 2. April 2026, am 2. Oktober 2026 und am 2. April 2027.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Levine Jon R

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 10/02/2025 M 11,517 A $0(1) 20,858,751 D
Common stock 10/02/2025 F 3,381(2) D $0.161 20,855,370 D
Common stock 6,684,640 I By the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 10/02/2025 M 11,517 (4) (4) Common Stock, par value $.001 per share 11,517 $0 34,552 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on April 2, 2024; the remaining RSUs will vest in three equal installments on each of April 2, 2026, October 2, 2026 and April 2, 2027 in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MRMD CEO Jon R. Levine report on 10/02/2025?

He reported the vesting and conversion of 11,517 RSUs into common stock and the withholding of 3,381 shares for tax obligations.

How many MRMD shares does Jon R. Levine beneficially own after the reported transactions?

The filing shows 20,855,370 shares owned directly following the transactions and 6,684,640 shares held indirectly by the Jon Levine Family Trust.

What was the withholding price per share for tax purposes on the RSU vesting?

The filing reflects withheld shares at a price of $0.161 per share.

When were the RSUs originally granted and when do remaining installments vest?

The RSUs were granted on April 2, 2024; remaining RSUs vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Does Jon R. Levine claim beneficial ownership of the shares held in the family trust?

No; the filing states the reporting person disclaims beneficial ownership of the 6,684,640 trust-held shares.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood